Pharmacodiagnotics through Molecular Clues

该项目是1B项目的延续。在过去的十年里，这个孢子发现了一组精选的 致病基因突变和显著过表达的基因。现在选择一个 这些线索中，很少有为合理的分子差异治疗靶向提供最好的希望， 来区分个体患者的肿瘤。 具体目标包括表征新的癌症突变，开发“药物诊断” 用于对个体患者进行遗传分类、治疗和建议，并揭示分子基础的算法 目前正在启动过表达的肿瘤抗原伴随抗原特异性治疗。 我们的长期目标是开发一种新的临床管理策略， 胰腺癌，将建议病人通过遗传咨询，建议外科医生和肿瘤学家 然后提供具体的工具，用于监测靶向药物的剂量和疗效， 治疗 我们将利用核心2的组织将该项目中的发现转化为早期患者筛查， 在拟议项目1A和3A中制定的，以及在项目3A中改进家庭遗传咨询的， 在核心3。 简单总结：为了使胰腺癌患者受益，我们需要更深入地了解 疾病的分子基础和最具体的药物靶点： 最早的阶段，了解其自然侵略过程的原因，并制定有效的 通过合理和个性化的方法进行治疗。这个项目将帮助我们理解 患者之间的差异，这将使我们能够选择适当的治疗方法，并提供适当的 遗传咨询

This project is a continuation of Project 1B. Over the past decade, this SPORE uncovered a select group of disease-causing gene mutations and conspicuously overexpressed genes. It is now appropriate to select a few of these clues that offer the best promise for rational therapeutic targeting of the molecular differences that distinguish the tumors of individual patients. The specific aims include the characterization of novel cancer mutations, to develop a "pharmacodiagnostic" algorithm for genetically classifying, treating and advising individual patients, and to uncover a molecular basis for overexpressed tumor antigens to accompany antigen-specific therapies now being initiated. Our long-term goals are to develop a new clinical management strategy for patients presenting with invasive pancreatic cancer that will advise the patient through genetic counseling, advise the surgeon and oncologist as to promising therapies, and then provide specific tools for monitoring the dosage and efficacy of targeted therapies. We will utilize tissues form Core 2 to translate discoveries made in this project to early patient screening being developed in proposed projects 1A and 3A and for improved genetic counseling of families in project 3A and in Core 3. Lay summary: In order to benefit pancreatic cancer patients, we will require a deeper understanding of the molecular basis of the disease and the most specific drug targets: to allow risk assessment and detection at the earliest stage, to understand the reasons for its naturally aggressive course, and to devise effective therapy through rational and individualized approaches. This project will help us to understand the key differences among patients that will enable us to select the proper therapies and provide the appropriate genetic counseling.